SCHEMBL705151

SCHEMBL705151

NC(=O)OC(=O)CC/C(=N/O)OC(N)=O

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2359064 0.81 ALDH1A1 (0.43) ALDH1A1
SCHEMBL238158 0.76 ALDH1A1 (0.32) ALDH1A1
SCHEMBL5968591 0.74 EGLN1 (0.39) ALDH1A1
SCHEMBL5785545 0.74 ALDH1A1 (0.38) ALDH1A1
SCHEMBL515928 0.74 ALDH1A1 (0.31) ALDH1A1
SCHEMBL731664 0.74 ALDH1A1 (0.46) ALDH1A1
SCHEMBL781568 0.72 ALDH1A1 (0.34) ALDH1A1
SCHEMBL10972290 0.72 ALDH1A1 (0.34) ALDH1A1
SCHEMBL733088 0.72 ALDH1A1 (0.62) ALDH1A1
SCHEMBL1768486 0.72 ALDH1A1 (0.34) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100221749-A1 THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF UNIVERSITE DE ROUEN 2010-09-02 US claimed
US-10260056-B2 Cleavage of fucose in N-glycans NEW ENGLAND BIOLABS, INC. (US) 2019-04-16 US disclosed
US-20180265854-A1 Cleavage of Fucose in N-Glycans NEW ENGLAND BIOLABS, INC. (US) 2018-09-20 US disclosed
EP-2252584-B1 COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS PROZYME INC (US) 2016-12-07 EP disclosed
EP-2317307-B1 Method of analyzing amino- and/or imino-functional compounds, and analytical reagent AJINOMOTO KK (JP) 2013-11-20 EP disclosed
US-8445292-B2 Compounds and methods for rapid labeling of N-glycans PROZYME, INC. (US) 2013-05-21 US disclosed
US-20120107942-A1 COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS PROZYME, INC. (US) 2012-05-03 US disclosed
US-8124792-B2 Compounds and methods for rapid labeling of N-glycans PROZYME, INC. (US) 2012-02-28 US disclosed
EP-2338057-A1 MASS MARKERS AND METHODS Brax Limited (GB) 2011-06-29 EP disclosed
US-20110152119-A1 Quantification Method of Biochemical Substances Using Ion Scattering Spectroscopy and Specific-Binding Efficiency Quantification Method of Biochemical Substances Using Ion Scattering Spectroscopy KOREA RESEARCH INSTITUTE OF STANDARDS AND SCIENCE (KR) 2011-06-23 US disclosed
US-20110143951-A1 MASS MARKERS AND METHODS BRAX LIMITED (GB) 2011-06-16 US disclosed
EP-2252584-A1 COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS Prozyme, Inc. (US) 2010-11-24 EP disclosed
US-20100221749-A1 THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF UNIVERSITE DE ROUEN 2010-09-02 US disclosed
WO-2010021509-A2 QUANTIFICATION METHOD OF BIOCHEMICAL SUBSTANCES USING ION SCATTERING SPECTROSCOPY AND SPECIFIC-BINDING EFFICIENCY QUANTIFICATION METHOD OF BIOCHEMICAL SUBSTANCES USING ION SCATTERING SPECTROSCOPY KOREA RESEARCH INSTITUTE OF STANDARDS AND SCIENCE (KR) 2010-02-25 WO disclosed
WO-2009153577-A1 MASS MARKERS AND METHODS BRAX LIMITED (GB) 2009-12-23 WO disclosed
US-20090258437-A1 COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS PROZYME, INC. (US) 2009-10-15 US disclosed
WO-2009100155-A1 COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS PROZYME, INC. (US) 2009-08-13 WO disclosed
EP-1252186-A2 USE OF NEUREGULIN-BETA AS AN INDICATOR AND/OR TARGET ProteoSys AG (DE) 2002-10-30 EP disclosed
WO-2001058948-A2 USE OF NEUREGULIN-β AS AN INDICATOR AND/OR TARGET PROTEOSYS AG (DE) 2001-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110143951-A1 MASS MARKERS AND METHODS PTMS, DCLRE1A, DCLRE1B ALDH1A1 3900/4885
US-20090258437-A1 COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS B3GNT2, FUT5, FUT6 ALDH1A1 2931/4885
US-20100221749-A1 THREE-FUNCTIONAL PSEUDO-PEPTIDIC REAGENT, AND USES AND APPLICATIONS THEREOF DNPEP, PEPD, LNPEP ALDH1A1 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.